Cancer risk and survival outcomes in germline POT1 variant carriers
Gene / mechanism
POT1
Germline pathogenic or likely pathogenic POT1 variants, and functionally assessed variants
Summary
The prevalence of germline POT1 variants, the associated tumour spectrum, cancer risk and survival outcomes were incompletely described, and clinical management guidelines vary. The authors studied carriers of pathogenic, likely pathogenic or functionally assessed variants in three biobanks (Penn Medicine Biobank, n = 51,172; Geisinger MyCode, n = 220,582; UK Biobank, n = 469,558) and a Penn Medicine clinical cohort. Estimated POT1 variant prevalence ranged from 1:1,279 to 1:2,902, and cancer diagnoses were more frequent in carriers than in non-carriers in all three biobanks (OR 3.41, 2.23 and 1.40). Cancer incidence increased from the mid-30s, without evidence of increased mortality, and lung cancer was associated with carrier status in two biobanks. The authors conclude that POT1 confers a moderately increased cancer risk (1.5- to 3.5-fold) with a broad tumour spectrum.
Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.
Analysis
The genotype-first biobank approach limits the ascertainment bias of family-based series and yields a moderate risk (1.5- to 3.5-fold). The lung cancer association and the absence of excess mortality await confirmation after peer review, especially as the carrier definition includes variants retained on functional data. For genetic counselling, these figures argue for surveillance proportionate to the risk rather than modelled on high-penetrance syndromes.
Analysis by Dr Thibaut Benquey
Why this score?
Clinical impact: 2/3 · Evidence strength: 3/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 0/1 → Total: 7/10
Keywords
More articles on POT1
Every Wednesday · Annotated selection · Free · Unsubscribe anytime